Home » Stocks » TARS

Tarsus Pharmaceuticals, Inc. (TARS)

Stock Price: $40.78 USD 0.06 (0.15%)
Updated Jan 25, 2021 2:07 PM EST - Market open
Market Cap 827.45M
Revenue (ttm) n/a
Net Income (ttm) -7.30M
Shares Out 19.26M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $40.78
Previous Close $40.72
Change ($) 0.06
Change (%) 0.15%
Day's Open 40.63
Day's Range 39.50 - 41.42
Day's Volume 32,074
52-Week Range 19.17 - 49.62

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthr...

GlobeNewsWire - 2 weeks ago

IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthr...

GlobeNewsWire - 2 weeks ago

IRVINE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthr...

GlobeNewsWire - 1 month ago

The Company began enrolling patients in Saturn-1 in September 2020 and expects to initiate its second pivotal registration trial, Saturn-2, in 2021 The Company began enrolling patients in Satu...

GlobeNewsWire - 1 month ago

IRVINE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthr...

GlobeNewsWire - 2 months ago

IRVINE, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthr...

GlobeNewsWire - 2 months ago

IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus” NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver...

GlobeNewsWire - 3 months ago

IRVINE, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (“Tarsus”), a late clinical-stage biopharmaceutical company focused on the development and commercialization of t...

Seeking Alpha - 3 months ago

Nine IPOs and five SPACs went public this past week, and one IPO postponed.

Other stocks mentioned: ALGS, ARRY, CDAK, EBC, OPT, PRAX, SPEL
GlobeNewsWire - 3 months ago

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of t...

About TARS

Tarsus Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase IIb/III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. Tarsus Pharmaceuticals, Inc. was founde... [Read more...]

Industry
Biotechnology
IPO Date
Oct 16, 2020
CEO
Dr. Bobak R. Azamian M.D.
Employees
18
Stock Exchange
NASDAQ
Ticker Symbol
TARS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 1.77% from the latest price.

Price Target
$41.50
(1.77% upside)
Analyst Consensus: Strong Buy